Monalizumab

CAS No. 1228763-95-8

Monalizumab( —— )

Catalog No. M36667 CAS No. 1228763-95-8

Monalizumab is a novel immune checkpoint inhibitor targeting natural killer cell population 2A (NKG2A).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 938 In Stock
10MG 1311 In Stock
25MG 1881 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Monalizumab
  • Note
    Research use only, not for human use.
  • Brief Description
    Monalizumab is a novel immune checkpoint inhibitor targeting natural killer cell population 2A (NKG2A).
  • Description
    Monalizumab (IPH2201) is an immune checkpoint inhibitor targeting Natural Killer Group 2A (NKG2A). Monalizumab, a humanized anti-NKG2A blocking mAb, increases IFN-γ production, thereby promoting NK cell effector functions. Monalizumab can be used for the research of head and neck squamous cell carcinoma (HNSCC).
  • In Vitro
    ——
  • In Vivo
    Animal Model:immunodeficient mice xenografted with Cal-27 HLA-E high tumor cellDosage:50?μg, together with 8?millions of activated NK cells Administration:intratumoral injections Result:Shows a synergestic antitumor effect.Enhanced NK-cell killing, and induces lysis of tumor cells.
  • Synonyms
    ——
  • Pathway
    Angiogenesis
  • Target
    Chk
  • Recptor
    Chk | IFNAR
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1228763-95-8
  • Formula Weight
  • Molecular Formula
    ——
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Thorbald van Hall, et al. Monalizumab: inhibiting the novel immune checkpoint NKG2A. J Immunother Cancer. 2019 Oct 17;7(1):263.?
molnova catalog
related products
  • LY2603618

    A potent and selective small molecule inhibitor of Chk1 (IC50=?7 nM); promotes impaired DNA synthesis and elevates H2A.X phosphorylation indicative of DNA damage and premature entry into mitosis.

  • PF-00477736

    PF-00477736 (PF-477736) is a potent, selective, ATP-competitive inhibitor of Chk1 with Ki of 0.49 nM, also inhibits Chk2 (Ki=47 nM) and poorly inhibits CDK1 activity (Ki=9.9 uM).

  • 4-Demethyldeoxypodop...

    4-Demethyldeoxypodophyllotoxin, an aryl tetrahydronaphthalenyl lignan analog from the roots of Podophyllum peltatum, has anticancer activity and modulates the Chk-2 signaling pathway in MCF-7 breast cancer cells.